Skip to main content

Table 1 Baseline characteristics of the incident NVAF cohort

From: Long-term vitamin K antagonists treatment patterns of Non-Valvular Atrial Fibrillation (NVAF): a population-based cohort study

  Total Men Women No initiation (within 3 months) VKA* initiation Antiplatelets* (only) initiation
  N (%) N (%) N (%) N (%) N (%) N (%)
Cohort size 135,241 64,786 (47.90) 70,455 (52.10) 34,659 (25.63) 51,794 (38.30) 48,788 (36.07)
Age, mean (SD) 75.09 (11.41) 73.29 (11.30) 76.73 (11.26) 72.54 (14.65) 75.95 (8.85) 75.98 (10.92)
18-49 4,526 (3.35) 2,643 (4.08) 1,883 (2.67) 2,918 (8.42) 525 (1.01) 1,083 (2.22)
50-59 6,770 (5.01) 3,948 (6.09) 2,822 (4.01) 2,558 (7.38) 1,697 (3.28) 2,515 (5.15)
60-69 22,730 (16.81) 12,736 (19.66) 9,994 (14.18) 6,027 (17.39) 8,408 (16.23) 8,295 (17.00)
70-79 51,018 (37.72) 26,376 (40.71) 24,642 (34.98) 10,977 (31.67) 22,533 (43.51) 17,508 (35.89)
80-89 40,769 (30.15) 16,403 (25.32) 24,366 (34.58) 9,369 (27.03) 16,503 (31.86) 14,897 (30.53)
≥90 9,428 (6.97) 2,680 (4.14) 6,748 (9.58) 2,810 (8.11) 2,128 (4.11) 4,490 (9.20)
Comorbidities
Hypertension 83,393 (61.66) 36,683 (56.62) 46,710 (66.30) 17,682 (51.02) 33,651 (64.97) 32,060 (65.71)
Myocardial infarction 27,909 (20.64) 16,186 (24.98) 11,723 (16.64) 3,475 (10.03) 10,081 (19.46) 14,353 (29.42)
Congestive heart failure 27,673 (20.46) 14,025 (21.65) 13,648 (19.37) 5,035 (14.53) 11,325 (21.87) 11,313 (23.19)
Prior stroke or TIA 11,654 (8.62) 5,644 (8.71) 6,010 (8.53) 1,726 (4.98) 5,088 (9.82) 4,840 (9.92)
Prior hemorrhage 21,080 (15.59) 11,160 (17.23) 9,920 (14.08) 6,452 (18.62) 6,437 (12.39) 8,191 (16.79)
Diabetes 34,337 (25.39) 17,893 (27.62) 16,444 (23.34) 6,318 (18.23) 13,688 (26.43) 14,331 (29.37)
Hyperlipidemia 57,433 (42.47) 30,360 (46.86) 27,073 (38.43) 8,165 (23.56) 23,688 (45.74) 25,580 (52.43)
Peripheral vascular disease 16,397 (12.12) 9,857 (15.21) 6,540 (9.28) 2,667 (7.69) 5,900 (11.39) 7,830 (16.05)
Chronic renal failure 14,467 (10.70) 8,228 (12.70) 6,239 (8.86) 3,124 (9.01) 4,960 (9.58) 6,383 (13.08)
Cancer 26,479 (19.58) 15,363 (23.71) 11,116 (15.78) 8,308 (23.97) 8,538 (16.48) 9,633 (19.74)
Charlson index, median (IQR) 1 (0-3) 1 (0-3) 1 (0-2) 1 (0-3) 1 (0-2) 1 (0-3)
0 50,090 (37.04) 21,300 (32.88) 28,790 (40.86) 14,295 (41.24) 20,308 (39.21) 15,487 (31.74)
1-2 49,213 (36.39) 23,036 (35.56) 26,177 (37.15) 11,517 (33.23) 19,606 (37.85) 18,090 (37.08)
≥3 35,938 (26.57) 20,450 (31.57) 15,488 (21.98) 8,847 (25.53) 11,880 (22.94) 15,211 (31.18)
CHADS2, median (IQR) 2 (1-3) 2 (1-2) 2 (1-3) 1 (1-2) 2 (1-3) 2 (1-3)
0 19,052 (14.09) 10,719 (16.55) 8,333 (11.83) 8,280 (23.89) 5,466 (10.55) 5,306 (10.88)
1 37,744 (27.91) 19,085 (29.46) 18,659 (26.48) 10,741 (30.99) 14,355 (27.72) 12,648 (25.92)
≥2 78,445 (58.00) 34,982 (54.00) 43,463 (61.69) 15,638 (45.12) 31,973 (61.73) 30,834 (63.20)
CHA2DS2-VASc, median (IQR) 3 (2-5) 3 (2-4) 4 (3-5) 3 (2-4) 4 (3-5) 4 (3-5)
0 4,209 (3.11) 4,209 (6.50) 0 (0.0) 2,212 (6.38) 875 (1.69) 1,122 (2.30)
1 11,530 (8.53) 7,962 (12.29) 3,568 (5.06) 4,973 (14.35) 3,380 (6.53) 3,177 (6.51)
≥2 119,502 (88.36) 52,615 (81.21) 66,887 (94.94) 27,474 (79.27) 47,539 (91.78) 44,489 (91.19)
HAS-BLED, median (IQR) 2 (1-3) 2 (1-3) 2 (1-3) 1 (1-2) 2 (1-3) 2 (2-3)
≤2 96,763 (71.55) 45,097 (69.61) 51,666 (73.33) 29,400 (84.83) 37,215 (71.85) 30,148 (61.79)
≥3 38,478 (28.45) 19,689 (30.39) 18,789 (26.67) 5,259 (15.17) 14,579 (28.15) 18,640 (38.21)
Medications
Antihypertensive drugs** 99,313 (73.43) 45,477 (70.20) 53.836 (76.41) 19,384 (55.93) 40,750 (78.68) 39,179 (80.30)
NSAIDs 49,164 (36.35) 21,617 (33.37) 27,547 (39.10) 12,496 (36.05) 19,003 (36.69) 17,665 (36.21)
Statins 52,132 (38.55) 27,934 (43.12) 24,198 (34.35) 6,873 (19.83) 21,703 (41.90) 23,556 (48.28)
  1. *Initiation within 3 months following NVAF diagnosis
  2. **Refers to angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers and diuretics
  3. Abbreviations: TIA transient ischemic attack, NSAIDs non-steroidal anti-inflammatory drugs